Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
dc.contributor.author | Smith, David C. | en_US |
dc.contributor.author | Chay, Christopher H. | en_US |
dc.contributor.author | Dunn, Rodney L. | en_US |
dc.contributor.author | Fardig, Judith | en_US |
dc.contributor.author | Esper, Peg | en_US |
dc.contributor.author | Olson, Karin B. | en_US |
dc.contributor.author | Pienta, Kenneth J. | en_US |
dc.date.accessioned | 2006-04-19T13:31:32Z | |
dc.date.available | 2006-04-19T13:31:32Z | |
dc.date.issued | 2003-07-15 | en_US |
dc.identifier.citation | Smith, David C.; Chay, Christopher H.; Dunn, Rodney L.; Fardig, Jude; Esper, Peg; Olson, Karin; Pienta, Kenneth J. (2003)."Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma." Cancer 98(2): 269-276. <http://hdl.handle.net/2027.42/34377> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34377 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12872344&dopt=citation | en_US |
dc.description.abstract | BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone-refractory prostate carcinoma. The authors conducted this clinical trial to evaluate the addition of carboplatin to the three-drug combination of paclitaxel, estramustine, and etoposide (TEE). METHODS Twenty patients with carcinoma of the prostate that was progressing despite hormone therapy were enrolled on this Phase II trial. Patients were treated with oral estramustine, 280 mg three times daily, and oral etoposide, 50 mg/m 2 , once daily on Days 1–7, with i.v. paclitaxel, 135 mg/m 2 , over 1 hour followed by carboplatin (area under the curve, 5) on Day 2 of each 21-day treatment cycle. Patients were evaluated for response after three cycles, and three additional cycles were given to responding or stable patients. RESULTS Nineteen patients were evaluable for response, and 12 patients had measurable disease at baseline. The measurable response rate was 58% (7 of 12 patients; 95% confidence interval [95% CI], 28–85%), and all of those were partial responses. Eleven patients had decreases > 50% from their baseline prostate specific antigen levels during therapy, for a response rate of 58% (95% CI, 34–80%) by this criterion. The median time to disease progression was 5.5 months, with a median survival of 14.2 months. Major toxicities included Grade (according to version 2 of the National Cancer Institute Common Toxicity Criteria) 4 neutropenia in 4 patients, Grade 4 thrombocytopenia in 4 patients, and anemia ≥ Grade 3 in 4 patients. One patient had a deep vein thrombosis. CONCLUSIONS The combination of TEEC was active in patients with hormone-refractory prostate carcinoma. The regimen was tolerable, with primarily hematologic toxicity. The addition of carboplatin to TEE did not appear to add to the efficacy of the three-drug combination of antimicrotubule agents. Cancer 2003;98:269–76. © 2003 American Cancer Society. DOI 10.1002/cncr.11494 | en_US |
dc.format.extent | 132359 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan ; University of Michigan Comprehensive Cancer Center, University of Michigan Medical Center, Ann Arbor, Michigan ; Fax: (734) 615-2719 ; Dr. David C. Smith received a research grant from Bristol-Myers Squibb. ; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, 7302 CCGC 0946, 1500 E. Medical Center Drive, Ann Arbor, MI 48109 | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, University of Michigan Medical Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan ; University of Michigan Comprehensive Cancer Center, University of Michigan Medical Center, Ann Arbor, Michigan | en_US |
dc.identifier.pmid | 12872344 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34377/1/11494_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.11494 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.